by Raynovich Rod | Jan 30, 2023 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
Update-4 Mixed stock market in healthcare and biotech but in an overall weak day as FED and CPI looms. IBB down 0.62% to $132 level. Abbvie (ABBV) beats with Revenue of $58.04B an increase of 3.3% but Humira biosimilars weigh on profit forecast ; pipeline and Botox...
by Raynovich Rod | Aug 30, 2021 | 2020-21 Life Science Portfolios
Update-1 3:45P 9/1 FDA issues warning on JAK Inhibitor drug class. ABBV down 7%., PFE and LLY drugs also affected. Small cap rally intact: CRSP,CYRX, VCYT. Quidel (QDEL) up 5.45% on need for more COVID tests. ARKG and XBI up about 1.5%. Mid-caps all green. IBB up...
by Raynovich Rod | Jun 10, 2019 | Biopharmaceuticals, Macro
Update-3 6/17 11:30 a EDT Pfizer (PFE) $11B Buyout of Array Pharmaceuticals (ARRY) Sparks Rally in biotech. As usual M&A brings buyers into biotech. ARRY up 56% on Pfizer $11B buyout. XBI up 3.68% to $84.46. Green screen in mid-caps, gene therapy. ==========...
by Raynovich Rod | Jun 5, 2019 | Biopharmaceuticals, Macro
Update-3…6/7- 1p EDT… Broad Tech Rally Underway Hot stocks in life science: CRSP, GILD, GSK, ILMN, VRTX, XBI up 1.56%. Update-2 …Bit of a rally at the close on the day-to-day tariff drama- now softening on Mexican tariffs; way too much obsession and...
by Raynovich Rod | May 21, 2019 | Biopharmaceuticals, Macro
Update-2…3:15p EDT…. Mixed day-new post after close, XBI down 0.64%, IBB down 0.94%,, Dow sell-off down 0.43%. ====== Update-1 5/22… Not much follow-through from yesterday but trade-able.A horrible news week with politics, tariffs, chips and China...
by Raynovich Rod | Apr 29, 2019 | Biopharmaceuticals
Large Cap Biopharma Stocks: Performance and Valuations for 2019. In 2019 the IBB was a less risky pick for a biopharma portfolio; ABBV and BMY look good. Merck (MRK) and Vertex (VRTX) were the top winners since 1/15/18. There was a severe correction in biopharma...
by Raynovich Rod | Apr 7, 2019 | Biopharmaceuticals
4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and “affordability board.” See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks...
by Raynovich Rod | Feb 4, 2019 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio, Clinical Diagnostics and Tools
Update 2/7/19 Mid-Day Trading : Risk Off Day The market is trending down with all major indices in the red and the XBI $81.96 down 2.75%. We sold our position in the XBI yesterday at $83+. Array (ARRY) continues to run up at $21.60. Hot stock MacroGenics (MGNX) cooled...
by Raynovich Rod | Jan 4, 2018 | 2020-21 Life Science Portfolios, Biopharmaceuticals, Life Science ETF's and Mutual Funds
Biotech ETF Performance Updates as of 4/11/18 YTD FBT First Trust NYSE Arca Biotech ETF is the leader in 2018. FBT up 7.45% Top Five Holdings are: AVXS, NKTR, XON, AGIO, TECH. The holdings are quite different than the large cap weighted FBIOX and IBB. XBI up 3.75% at...
by Raynovich Rod | Jun 22, 2017 | Biopharmaceuticals
6/27/17 Red Screen Day: Sell-Off in Biotechs Possibly Due to Senate Delay in Healthcare Vote IBB down 1.54% at $314.80. Momentum stocks are weak; NASDAQ down 1.2%. Take profits on XBI trade at $78 range after 34% move YTD. Allow time for arm twisting by Republicans...